Answers are grounded in this paper and cite their sources.
To the Editor: Inadequate access to buprenorphine impedes care in the current opioid crisis.Pharmacists may be able to expand access to this medication with the use of collaborative practice agreements 1,2 that allow prescribers to delegate evaluation and some treatment decisions to pharmacists.Rhode Island amended a collaborative practice agreement to incorporate induction with buprenorphine, the first-line medication approved by the Food and Drug Administration for the treatment of opioid withdrawal and opioid use disorder.traci.c.
No takes yet. Share an insight, caveat, or question.
Green et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: